<?xml version='1.0' encoding='utf-8'?>
<document id="17434849"><sentence text="Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study."><entity charOffset="0-11" id="DDI-PubMed.17434849.s1.e0" text="Pravastatin" /></sentence><sentence text="The objectives of the study were to assess the effects of pravastatin on plasma HIV RNA, lipid parameters, and protease inhibitor (PI) concentrations in patients treated with PI-containing regimens and with total cholesterol (TC) &gt; or = 5"><entity charOffset="58-69" id="DDI-PubMed.17434849.s2.e0" text="pravastatin" /><entity charOffset="213-224" id="DDI-PubMed.17434849.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.17434849.s2.e0" e2="DDI-PubMed.17434849.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17434849.s2.e0" e2="DDI-PubMed.17434849.s2.e1" /></sentence><sentence text="5 mmol/L" /><sentence text="" /><sentence text="A clinical trial including patients randomized to receive pravastatin or matching placebo for 12 weeks was implemented"><entity charOffset="58-69" id="DDI-PubMed.17434849.s5.e0" text="pravastatin" /></sentence><sentence text="" /><sentence text="Twelve patients were included in the pravastatin group and 9 in the placebo group"><entity charOffset="37-48" id="DDI-PubMed.17434849.s7.e0" text="pravastatin" /></sentence><sentence text=" At week 12 (W12), no patient had experienced virological failure" /><sentence text=" Between week 0 (W0) and W12, the median differences for TC were -1" /><sentence text="4 mmol/L in the pravastatin group and +0"><entity charOffset="16-27" id="DDI-PubMed.17434849.s10.e0" text="pravastatin" /></sentence><sentence text="2 mmol/L in the placebo group (p = " /><sentence text="005); for LDL, they were -1" /><sentence text="0 mmol/L and +0" /><sentence text="3 (p = " /><sentence text="007), respectively" /><sentence text=" A significant decrease of the PI concentration (12 hours after administration) ratio W12 - W0/W0 was noticed in the pravastatin group (-0"><entity charOffset="117-128" id="DDI-PubMed.17434849.s16.e0" text="pravastatin" /></sentence><sentence text="2 [interquartile range, -0" /><sentence text="3 to -0" /><sentence text="1] as compared with the placebo group (0" /><sentence text="1 [IQR, 0" /><sentence text="0 to 0" /><sentence text="3]) (p = " /><sentence text="03)" /><sentence text=" When the study was restricted to patients treated with lopinavir/ritonavir, a decrease from 3"><entity charOffset="56-65" id="DDI-PubMed.17434849.s24.e0" text="lopinavir" /><entity charOffset="66-75" id="DDI-PubMed.17434849.s24.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.17434849.s24.e0" e2="DDI-PubMed.17434849.s24.e0" /><pair ddi="false" e1="DDI-PubMed.17434849.s24.e0" e2="DDI-PubMed.17434849.s24.e1" /></sentence><sentence text="8 microg/mL at baseline to 2" /><sentence text="9 mug/mL at W12 was noticed in the pravastatin arm (p = "><entity charOffset="35-46" id="DDI-PubMed.17434849.s26.e0" text="pravastatin" /></sentence><sentence text="04) but not in the control arm (p = 1" /><sentence text="00)" /><sentence text=" No clinical adverse event reached a severity of grade 3" /><sentence text="" /><sentence text="We observed in this study that the use of pravastatin in PI-treated patients was not associated with major change in the plasma HIV RNA on 12 weeks of follow-up"><entity charOffset="42-53" id="DDI-PubMed.17434849.s31.e0" text="pravastatin" /></sentence><sentence text=" However, we found a trend of decrease of the trough PI concentration at W12, suggesting a possible drug-drug interaction of pravastatin on PI metabolism"><entity charOffset="125-136" id="DDI-PubMed.17434849.s32.e0" text="pravastatin" /></sentence><sentence text="" /></document>